The SORIN Group, which operates in the medical sector for the treatment of cardiovascular disease, has obtained funding of 100 million euros from the European Investment Bank (EIB). The loan is intended for research and development (R&D) projects in France and Italy to develop new products or improve existing ones in the Cardiac Surgery, Cardiac Rhythm Management and New Ventures segments. The projects concerned cover the development of pre-clinical and clinical trials for 2014-2016, with funding representing about one third of the investment planned by SORIN in Italy and France for the period. In 2013, SORIN invested about 10% of its revenue in R&D, in which about 15% of its staff are engaged in its research centres in Italy, France, Germany and North America. The 7-year loan from the EIB offers competitive terms with respect to market benchmarks. Source: Il Sole 24 Ore Radiocor.
More news, in Italian, from France, China, Germany, Spain, the EU, the Czech Republic and the UK.
